Holen Sie sich die Stockscreener-App
6.16
3.36%
0.20
Handel nachbörslich:
6.12
-0.04
-0.65%
Schlusskurs vom Vortag:
$5.96
Offen:
$6.03
24-Stunden-Volumen:
2.00M
Relative Volume:
1.21
Marktkapitalisierung:
$857.01M
Einnahmen:
$62.04M
Nettoeinkommen (Verlust:
$-533.34M
KGV:
-1.5714
EPS:
-3.92
Netto-Cashflow:
$-473.07M
1W Leistung:
+2.16%
1M Leistung:
-5.23%
6M Leistung:
+16.89%
1J Leistung:
-21.93%
1-Tages-Spanne:
$5.934
$6.295
1-Wochen-Bereich:
$5.55
$6.295
52-Wochen-Spanne:
$4.155
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
Firmenname
Vir Biotechnology Inc
Sektor
Branche
Telefon
415-906-4324
Adresse
1800 OWENS STREET, SAN FRANCISCO, CA
Vergleichen Sie VIR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
6.16 | 829.19M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-03 | Eingeleitet | Evercore ISI | Outperform |
| 2025-08-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-03-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-02-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | Eingeleitet | SVB Leerink | Outperform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-03-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-22 | Herabstufung | Goldman | Buy → Neutral |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-01-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-09-14 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-11 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-08-20 | Eingeleitet | Needham | Buy |
| 2020-03-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2020-02-27 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2019-11-05 | Eingeleitet | Barclays | Overweight |
| 2019-11-05 | Eingeleitet | Cowen | Outperform |
| 2019-11-05 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten
Hepatitis B Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | Arbutus Biopharma, GSK/Ionis Pharma, Vir Biotech, Dong-A ST Co., Ltd., Barinthus Biotherapeutics, GC Biopharma Corp - The Globe and Mail
Vir Biotechnology issues license to Norgine to market hepatitis D candidate - MSN
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Vicki Sato Sells 22,000 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus
Sell Signal: Will Vir Biotechnology Inc stock benefit from M A activityJuly 2025 Decliners & Expert Verified Movement Alerts - moha.gov.vn
What is HC Wainwright's Forecast for VIR FY2025 Earnings? - MarketBeat
Aug PreEarnings: Why Vir Biotechnology Inc stock remains resilientJuly 2025 Retail & Real-Time Volume Analysis Alerts - moha.gov.vn
Vir Biotechnology (NASDAQ:VIR) Stock Price Down 3.4%Here's What Happened - MarketBeat
VIR: HC Wainwright & Co. Reiterates 'Buy' Rating with $15 Price Target | VIR Stock News - GuruFocus
H.C. Wainwright reiterates Buy rating on Vir Biotechnology stock By Investing.com - Investing.com Canada
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Can Vir Biotechnology Inc. stock beat market expectations this quarterEarnings Risk Report & Stepwise Trade Signal Implementation - Улправда
EV Market: Can Vir Biotechnology Inc. stock resist market sell offsEarnings Recap Summary & Precise Buy Zone Tips - Улправда
Aug Swings: Will Vir Biotechnology Inc stock benefit from M A activityOptions Play & Weekly Sector Rotation Insights - moha.gov.vn
Why analysts remain bullish on Vir Biotechnology Inc. stock2025 Bull vs Bear & Accurate Intraday Trading Signals - Улправда
Is Vir Biotechnology Inc. stock a buy for dividend growthJuly 2025 Highlights & Weekly Breakout Stock Alerts - Улправда
Momentum Shift: Can Vir Biotechnology Inc. stock beat market expectations this quarterJuly 2025 Highlights & Weekly Stock Breakout Alerts - Улправда
Can Vir Biotechnology Inc. stock sustain revenue growthQuarterly Portfolio Summary & AI Forecast for Swing Trade Picks - DonanımHaber
Will Vir Biotechnology Inc. stock outperform value stocks2025 Short Interest & Weekly High Return Stock Opportunities - DonanımHaber
Published on: 2025-12-19 13:20:41 - Улправда
How Vir Biotechnology Inc. stock performs after earnings2025 Trading Volume Trends & Technical Entry and Exit Tips - Улправда
Will Vir Biotechnology Inc. stock recover faster than market2025 Sector Review & Reliable Breakout Forecasts - Улправда
Latham Advises Norgine on Exclusive Licensing Agreement With Vir Biotechnology - Legal Desire Media and Insights
Vir Biotechnology stock gains on Norgine partnership for Hepatitis Delta program - Investing.com Canada
Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology | Corporate - EQS News
Norgine Pharmaceuticals Limited - AD HOC NEWS
EQS-News: Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnologyboerse.de - boerse.de
Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology - PR Newswire
Vir Biotechnology Licenses CHD Combination Therapy to Norgine for Europe, Australia, New Zealand - marketscreener.com
Vir Biotechnology Secures Licensing Deal with Norgine - TipRanks
Vir Biotechnology licenses hepatitis delta treatment to Norgine in €550m deal - Investing.com Canada
Vir Biotechnology licenses hepatitis delta treatment to Norgine in €550m deal By Investing.com - Investing.com South Africa
Vir Biotechnology (VIR) Secures Exclusive Licensing Deal with No - GuruFocus
[8-K] Vir Biotechnology, Inc. Reports Material Event | VIR SEC FilingForm 8-K - Stock Titan
Vir Biotechnology stock rises after licensing hepatitis delta treatment By Investing.com - Investing.com Canada
Vir Biotechnology grants Norgine exclusive commercial license to chronic hepatitis delta treatment candidate - marketscreener.com
Vir Biotechnology Grants Norgine Exclusive Commercial License To Chronic Hepatitis Delta Treatment Candidate - TradingView — Track All Markets
Vir Biotechnology signs agreement with Norgine for hepatitis Delta treatment - Traders Union
Vir Biotechnology grants Norgine exclusive license for hepatitis delta treatment - StreetInsider
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program - Business Wire
Vir Biotechnology Earnings Notes - Trefis
12,916,663 Shares in Vir Biotechnology, Inc. $VIR Bought by ARCH Venture Management LLC - MarketBeat
Vir Biotechnology, Inc. (VIR) Stock Analysis: Uncovering The 159.76% Potential Upside - DirectorsTalk Interviews
Vir Biotechnology stock gets positive readthrough from Mirum’s Bluejay deal By Investing.com - Investing.com Canada
Vir Biotechnology stock gets positive readthrough from Mirum’s Bluejay deal - Investing.com
After Losing 25% in the Past Year, Vir Biotechnology, Inc. (NASDAQ:VIR) Institutional Owners Must Be Relieved by the Recent Gain - 富途牛牛
Vir Biotechnology (VIR) Gains Positive Outlook Amid Industry Acq - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Shares Gap UpShould You Buy? - MarketBeat
Vir Biotechnology Insiders Sold US$1.1m Of Shares Suggesting Hesitancy - simplywall.st
Can Vir Biotechnology (NASDAQ:VIR) Afford To Invest In Growth? - Yahoo Finance
Finanzdaten der Vir Biotechnology Inc-Aktie (VIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
28.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):